昭衍新药
(603127)
| 流通市值：217.14亿 | | | 总市值：258.12亿 |
| 流通股本：6.30亿 | | | 总股本：7.49亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 984,961,529.76 | 668,575,211.14 | 287,337,235.01 | 2,018,333,771.81 |
| 营业收入 | 984,961,529.76 | 668,575,211.14 | 287,337,235.01 | 2,018,333,771.81 |
| 二、营业总成本 | 1,025,427,901.11 | 667,394,336.77 | 288,252,886.21 | 1,763,748,341.31 |
| 营业成本 | 772,681,388.3 | 507,935,259.42 | 205,132,917.71 | 1,444,560,234.36 |
| 税金及附加 | 6,178,941.53 | 4,317,229.34 | 1,352,112.14 | 8,981,402.37 |
| 销售费用 | 22,041,852.96 | 14,608,733.68 | 6,079,268.59 | 27,881,056.45 |
| 管理费用 | 213,574,864.2 | 134,505,155.96 | 71,784,152.89 | 289,180,575.62 |
| 研发费用 | 63,864,270.44 | 43,446,069.62 | 23,027,883.99 | 92,918,280.66 |
| 财务费用 | -52,913,416.32 | -37,418,111.25 | -19,123,449.11 | -99,773,208.15 |
| 其中:利息费用 | 1,079,303.33 | 776,460.21 | 521,186.18 | 2,448,073.47 |
| 其中:利息收入 | 59,549,247.23 | 41,322,974.41 | 21,160,369.25 | 103,230,766.43 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 169,197,862.53 | 107,019,073.28 | 65,875,504.16 | -127,048,597.78 |
| 加:投资收益 | 20,033,342.3 | 13,135,262.03 | 1,235,855.96 | 36,011,545.69 |
| 资产处置收益 | -15,902.95 | -44,025.87 | - | -48,130.43 |
| 资产减值损失(新) | -76,295,444.28 | -66,010,456.08 | -32,494,609.52 | -66,540,016.67 |
| 信用减值损失(新) | 2,285,614.08 | 5,391,403.55 | 10,411,088.36 | -19,140,159.62 |
| 其他收益 | 24,712,928.01 | 19,183,378.08 | 5,270,400.41 | 26,527,237.43 |
| 四、营业利润 | 99,452,028.34 | 79,855,509.36 | 49,382,588.17 | 104,347,309.12 |
| 加:营业外收入 | 387,234.69 | 319,690.6 | 48,408.25 | 223,456.84 |
| 减:营业外支出 | 213,878.21 | 55,626.21 | 47,246.62 | 531,692.34 |
| 五、利润总额 | 99,625,384.82 | 80,119,573.75 | 49,383,749.8 | 104,039,073.62 |
| 减:所得税费用 | 18,919,337.5 | 19,187,197.37 | 8,264,284.55 | 34,284,009.72 |
| 六、净利润 | 80,706,047.32 | 60,932,376.38 | 41,119,465.25 | 69,755,063.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 80,706,047.32 | 60,932,376.38 | 41,119,465.25 | 69,755,063.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 80,706,068 | 60,932,399.37 | 41,119,492.23 | 74,075,384.59 |
| 少数股东损益 | -20.68 | -22.99 | -26.98 | -4,320,320.69 |
| 扣除非经常损益后的净利润 | 29,044,730.55 | 23,052,174.74 | 25,662,551.81 | 23,573,407.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.08 | 0.05 | 0.1 |
| (二)稀释每股收益 | 0.11 | 0.08 | 0.05 | 0.1 |
| 八、其他综合收益 | -6,480,220.42 | -2,334,068.82 | -766,939.36 | -51,041,084.41 |
| 归属于母公司股东的其他综合收益 | -6,480,220.42 | -2,334,068.82 | -766,939.36 | -51,041,084.41 |
| 九、综合收益总额 | 74,225,826.9 | 58,598,307.56 | 40,352,525.89 | 18,713,979.49 |
| 归属于母公司股东的综合收益总额 | 74,225,847.58 | 58,598,330.55 | 40,352,552.87 | 23,034,300.18 |
| 归属于少数股东的综合收益总额 | -20.68 | -22.99 | -26.98 | -4,320,320.69 |
| 公告日期 | 2025-10-31 | 2025-08-27 | 2025-04-29 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |